歌禮制藥-B(01672.HK):PD-L1抗體ASC22乙肝功能性治癒臨牀研究被AASLD評議委員會選為“大會最佳摘要”
格隆匯11月16日丨歌禮制藥-B(01672.HK)發佈公吿,PD-L1抗體ASC22(恩沃利單抗)用於乙肝功能性治癒的IIa期和IIb期臨牀研究入選2021年美國肝病研究協會(AASLD)年會(The Liver Meeting® 2021)“大會最佳摘要合集病毒性肝炎類”。兩項臨牀研究的主講人從AASLD主席處獲悉此榮譽,其表示“...入選該論文合集是一種殊榮,表明AASLD評議委員會對您的研究給予了高度評價...。”
IIa期和IIb期研究的重點是使用皮下注射PD-L1抗體ASC22(恩沃利單抗)實現慢性乙型肝炎(CHB)的功能性治癒。這兩項臨牀研究的標題是:(1)皮下注射PD-L1抗體ASC22(恩沃利單抗)治療慢性乙型肝炎患者的IIa期試驗;和(2)皮下注射PD-L1抗體ASC22(恩沃利單抗)聯合核苷(酸)類似物治療在慢性乙型肝炎患者中實現乙肝表面抗原消失:IIb期臨牀試驗的中期結果。
Follow us
Find us on
Facebook,
Twitter ,
Instagram, and
YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the
uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!

Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.